abstract |
The present invention relates to the general formula (I) for the treatment of NK-I receptor related diseases, wherein R is methyl; and R 1 is 4-methyl-4-oxy-piperazin-1-yl Or R is CH 2 OH and R 1 is 4-methyl-piperazin-1-yl or 4-methyl-4-oxy-piperazin-1-yl), and pharmaceutically acceptable compounds thereof The acid addition salt. |